12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Other News

QuantuMdx, The Technology Strategy Board (TSB) diagnostic news

QuantuMDx received £1.4 million ($2.2 million) from the TSB's Biocatalyst Fund for the biotech's Q-Cancer project. Under the project, the company aims to develop a...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >